$2.84
2.90% day before yesterday
Nasdaq, Oct 03, 10:00 pm CET
ISIN
US28617K1016
Symbol
ELDN

Eledon Pharmaceuticals Inc Stock price

$2.84
+0.25 9.65% 1M
-0.32 10.13% 6M
-1.28 31.07% YTD
+0.29 11.37% 1Y
+0.09 3.27% 3Y
-15.49 84.51% 5Y
-1,834.24 99.85% 10Y
-3,846.28 99.93% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
+0.08 2.90%
ISIN
US28617K1016
Symbol
ELDN
Industry

Key metrics

Basic
Market capitalization
$170.1m
Enterprise Value
$62.5m
Net debt
positive
Cash
$107.6m
Shares outstanding
59.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
66.6%
Return on Equity
-30.6%
ROCE
-67.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-87.9m | $-91.7m
Net Income
$-10.3m | $-51.8m
Free Cash Flow
$-64.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-52.1% | -29.9%
Net Income
88.9% | -43.3%
Free Cash Flow
-70.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.1
FCF per Share
$-1.1
Short interest
10.1%
Employees
31
Rev per Employee
$0.0
Show more

Is Eledon Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Eledon Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Eledon Pharmaceuticals Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Eledon Pharmaceuticals Inc forecast:

Buy
92%
Hold
8%

Financial data from Eledon Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
10% 10%
-
- Research and Development Expense 68 68
71% 71%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -88 -88
52% 52%
-
Net Profit -10 -10
89% 89%
-

In millions USD.

Don't miss a Thing! We will send you all news about Eledon Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eledon Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
11 days ago
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D.
Neutral
GlobeNewsWire
about one month ago
IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Neutral
GlobeNewsWire
about 2 months ago
Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m 2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in kidney transplantation in November 2025 Cash, cash equivalents and short-term investments of $107.6 million as of June 30, 2025 IRVINE, Calif., Aug. 14, 2025 (...
More Eledon Pharmaceuticals Inc News

Company Profile

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.

Head office United States
CEO David-Alexandre Gros
Employees 31
Founded 2004
Website eledon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today